EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions

Matthew Rubinstein, Madeline Lauren Hong, Rishi Kumar Nanda, Daniel Thomas Jones, Hazem Aboaid, Yin Mon Myat, Kyaw Zin Thein

Oncology Research · 2025

DOI: 10.32604/or.2025.067791 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Matthew Rubinstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Osteopathic Medicine, Touro University, Henderson, NV 89014, USA. Hauptthemen laut MEDLINE: Neoplasms, Molecular Targeted Therapy, Precision Medicine, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ever-expanding development of tissue-agnostic therapies which target malignancies based on specific mutations rather than tissue origin have transformed the landscape of oncology. The purpose of this review is to explore the impact, safety, and challenges of tissue-agnostic therapies including pembrolizumab, dostarlimab, larotrectinib, entrectinib, repotrectinib, dabrafenib plus trametinib, selpercatinib, and trastuzumab deruxtecan. As the therapeutic arsenal continues to grow, it is crucial to understand how these therapies truly benefit patients and to address the barriers that stand in the way of making them more widely available. Although these therapies have shown effectiveness across multiple cancer types, substantial challenges persist, including overcoming the burden of intratumoral heterogeneity and resistance mechanisms that reduce therapeutic efficacy. We discuss emergence of pan-histological biomarkers, such as neoantigen burden, current updates on trials as well as trial outlining strategies to refining patient selection, while also supporting broader access to biomarker testing. Collectively, these insights underscore the transformative role of tissue-agnostic therapies in precision oncology while emphasizing the ongoing need for research to optimize their application and overcome current barriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMolecular Targeted TherapyPrecision MedicineAntineoplastic AgentsHumansBiomarkers, TumorDrug Approval

Stichwörter der Autor:innen

Tissue-agnostic drugsadvances in cancer therapeuticsprecision oncology updates

Substanzen

Biomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • College of Osteopathic Medicine, Touro University, Henderson, NV 89014, USA.
  • Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA.
  • Department of Internal Medicine, One Brooklyn Health-Interfaith Medical Center Campus, Brooklyn, NY 11213, USA.
  • Division of Hematology and Medical Oncology, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV 89169, USA.

Zitieren

APA

Rubinstein, M., Hong, M. L., Nanda, R. K., Jones, D. T., Aboaid, H., Myat, Y. M., & Thein, K. Z. (2025). Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions. Oncology Research. https://doi.org/10.32604/or.2025.067791

Vancouver

Rubinstein M, Hong ML, Nanda RK, Jones DT, Aboaid H, Myat YM, et al. Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions. Oncology Research. 2025. doi:10.32604/or.2025.067791

BibTeX
@article{Rubinstein2025,
  author = {Rubinstein, Matthew and Hong, Madeline Lauren and Nanda, Rishi Kumar and Jones, Daniel Thomas and Aboaid, Hazem and Myat, Yin Mon and Thein, Kyaw Zin},
  title = {Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.067791}
}
Kostenlos starten →